APA (7th ed.) Citation

CD, F., N, S., H, S., R, G., W, M., T, S., . . . M, T. (2023). Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis. JHEP reports : innovation in hepatology, 5(11), 100874. https://doi.org/10.1016/j.jhepr.2023.100874

Chicago Style (17th ed.) Citation

CD, Fuchs, et al. "Non-steroidal FXR Agonist Cilofexor Improves Cholestatic Liver Injury in the Mdr2-/- Mouse Model of Sclerosing Cholangitis." JHEP Reports : Innovation in Hepatology 5, no. 11 (2023): 100874. https://doi.org/10.1016/j.jhepr.2023.100874.

MLA (9th ed.) Citation

CD, Fuchs, et al. "Non-steroidal FXR Agonist Cilofexor Improves Cholestatic Liver Injury in the Mdr2-/- Mouse Model of Sclerosing Cholangitis." JHEP Reports : Innovation in Hepatology, vol. 5, no. 11, 2023, p. 100874, https://doi.org/10.1016/j.jhepr.2023.100874.